Results of a study investigating pembrolizumab combined with rituximab for treatment of Waldenstom Macroglobulinemia.
Home / Resource Library / PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenstrom Macroglobulinaemia